Study of Changes and Characteristics of Genes in Patients With Pancreatic Cancer for Better Treatment Selection (COMPASS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02750657 |
Recruitment Status :
Active, not recruiting
First Posted : April 25, 2016
Last Update Posted : December 1, 2021
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment |
---|---|
Carcinoma, Pancreatic Ductal | Genetic: Molecular Profiling |
Study Type : | Observational |
Actual Enrollment : | 332 participants |
Observational Model: | Cohort |
Time Perspective: | Prospective |
Official Title: | Comprehensive Molecular Characterization of Advanced Pancreatic Ductal Adenocarcinomas (PDAC) for Better Treatment Selection: A Prospective Study |
Actual Study Start Date : | December 2015 |
Estimated Primary Completion Date : | June 2022 |
Estimated Study Completion Date : | December 2022 |

Group/Cohort | Intervention/treatment |
---|---|
Patients with advanced pancreatic ductal adenocarcinoma |
Genetic: Molecular Profiling
Whole Genome Sequencing |
- The feasibility of prospectively identifying subgroups of patients with advanced PDAC who have distinct genomic characteristics for better treatment selection while undergoing 1st-line chemotherapy using next generation sequencing. [ Time Frame: 8 weeks ]
- Disease control rate achieved by m-FOLFIRINOX [ Time Frame: 5 years ]
- Disease control rate achieved by nab-paclitaxel [ Time Frame: 5 years ]
- Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to m-FOLFIRINOX [ Time Frame: 5 years ]
- Duration of response defined as the interval between the first date of complete response or partial response and the earliest date of disease progression or death due to any cause to nab-paclitaxel. [ Time Frame: 5 years ]
- Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with m-FOLFIRINOX. [ Time Frame: 5 years ]
- Progression free survival defined as the interval between the date of registration and the earliest date of disease progression or death due to any cause of patients treated with nab-paclitaxel. [ Time Frame: 5 years ]
- Overall survival defined as the interval between the date of registration and the date of death of patients treated with m-FOLFIRINOX [ Time Frame: 5 years ]
- Overall survival defined as the interval between the date of registration and the date of death of patients treated with nab-paclitaxel. [ Time Frame: 5 years ]
- Correlation between tumor genomic characteristics and m-FOLFIRINOX response using next generation sequencing. [ Time Frame: 5 years ]
- Correlation between tumor genomic characteristics and nab-paclitaxel response using the next generation sequencing. [ Time Frame: 5 years ]
- Percentage of patients with germline BRCA, PALB2 and ATM mutations who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibition. [ Time Frame: 5 years ]
- Percentage of patients with somatic DSBR deficiency who might benefit from a personalized treatment strategy such as combination of cisplatin and a PARP inhibitor. [ Time Frame: 5 years ]
- Percentage of patients who might benefit from immunotherapy (patients with smoking genomic signatures, patients with a hypermutated phenotype, patients with mismatch repair deficiency and patients with tumor neo-antigen expression). [ Time Frame: 5 years ]
- Percentage of patients with rare but targetable somatic mutations. [ Time Frame: 5 years ]
- Difference in disease control rate between patients with tumor smoking signature and those without. [ Time Frame: 5 years ]
- Difference in overall survival between patients with tumor smoking signature and those without. [ Time Frame: 5 years ]
- Correlation with tumor molecular characteristics and toxicities to treatment using next generation sequencing. [ Time Frame: 5 years ]
Biospecimen Description:
- Fresh tumor tissue biopsy samples
- Archival tumor tissue samples
- Whole blood samples
- Plasma samples
- Serum samples

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients must have a histological or radiological diagnosis of locally advanced or metastatic pancreatic ductal adenocarcinoma. Patients with borderline resectable disease are not eligible.
- Patient must have a tumor lesion that is amenable to a core needle biopsy.
- Patients must have a measurable lesion by RECIST 1.1 in addition to the lesion that is going to be biopsied.
- Patients must be fit enough to safely undergo a tumor biopsy.
- Age 18 years or older.
- Eastern Cooperative Group (ECOG) performance status of 1 or less.
- Life expectancy of greater than 90 days.
- Patients must have normal organ and marrow function
- Patients must undergo systemic treatment with m-FOLFIRINOX or nab-paclitaxel as a first line standard systemic palliative treatment or combination treatment with m-FOLFIRINOX or nab-paclitaxel with or without other investigational agents within a clinical trial as a first line palliative treatment.
- Ability to understand and willing to sign a written informed consent document.
Exclusion Criteria:
- Patients with one or more contraindications to tumor biopsy.
- Patients who have prior systemic treatment (chemotherapy or any other anti-cancer agent) in advanced setting.
- Patients who are currently on anti-cancer treatment including chemotherapy.
- Patients with known brain metastases.
- Patients with advanced PDAC who are going to be treated with gemcitabine monotherapy in advanced setting.
- Uncontrolled inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
- Any other condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns or compliance with clinical study procedures.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02750657
Canada, Ontario | |
Kingston Health Sciences Centre | |
Kingston, Ontario, Canada, K7L2V7 | |
Princess Margaret Cancer Centre | |
Toronto, Ontario, Canada, M5G 2M9 | |
Canada, Quebec | |
Centre Hospitalier de l'Universite de Montreal (CHUM) | |
Montréal, Quebec, Canada, H2X 3E4 | |
McGill University Health Centre | |
Montréal, Quebec, Canada, H4A3J1 |
Principal Investigator: | Jennifer J. Knox, M.D. | Princess Margaret Cancer Centre |
Responsible Party: | University Health Network, Toronto |
ClinicalTrials.gov Identifier: | NCT02750657 |
Other Study ID Numbers: |
COMPASS-001 |
First Posted: | April 25, 2016 Key Record Dates |
Last Update Posted: | December 1, 2021 |
Last Verified: | November 2021 |
Carcinoma, Pancreatic Ductal Carcinoma, Ductal Adenocarcinoma Carcinoma Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Ductal, Lobular, and Medullary |
Pancreatic Neoplasms Digestive System Neoplasms Neoplasms by Site Endocrine Gland Neoplasms Digestive System Diseases Pancreatic Diseases Endocrine System Diseases |